Search Results - "REYNO, L"

Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and Pain by ERNST, D. S, TANNOCK, I. F, WINQUIST, E. W, VENNER, P. M, REYNO, L, MOORE, M. J, CHI, K, DING, K, ELLIOTT, C, PARULEKAR, W

“…To compare the incidence of palliative response in patients with hormone-resistant prostate cancer (HRPC) treated with mitoxantrone and prednisone (MP) plus…”
Get full text

Helping Patients Make Informed Choices: A Randomized Trial of a Decision Aid for Adjuvant Chemotherapy in Lymph Node-Negative Breast Cancer by Whelan, Timothy, Sawka, Carol, Levine, Mark, Gafni, Amiram, Reyno, Leonard, Willan, Andrew, Julian, Jim, Dent, Susan, Abu-Zahra, Hakam, Chouinard, Edmond, Tozer, Richard, Pritchard, Kathleen, Bodendorfer, Ilona

“…Background: In recent years, patients have indicated a desire for more information about their disease and to be involved in making decisions about their care…”
Get full text

Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer by Wolpin, B.M., O'Reilly, E.M., Ko, Y.J., Blaszkowsky, L.S., Rarick, M., Rocha-Lima, C.M., Ritch, P., Chan, E., Spratlin, J., Macarulla, T., McWhirter, E., Pezet, D., Lichinitser, M., Roman, L., Hartford, A., Morrison, K., Jackson, L., Vincent, M., Reyno, L., Hidalgo, M.

“…We evaluated AGS-1C4D4, a fully human monoclonal antibody to prostate stem cell antigen (PSCA), with gemcitabine in a randomized, phase II study of metastatic…”
Get full text

Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone by SMALL, E. J, MEYER, M, MARSHALL, M. E, REYNO, L. M, MEYERS, F. J, NATALE, R. B, LENEHAN, P. F, LIANG CHEN, SLICHENMYER, W. J, EISENBERGER, M

“…Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC). A prospective…”
Get full text

480 Detection by Immunohistochemistry of Prostate Stem Cell Antigen (PSCA) in Tumors is Not a Predictive Biomarker for the Anti-PSCa Monoclonal Antibody AGS-1C4D4: Identification of Alternative Predictive Biomarkers by Doñate, F, Hartford, A, Morrison, K, da Cruz, L, Nater, J, Brooks, T, Ou, J, Chalita-Eid, P, Stover, D, Reyno, L

Get full text

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy by Sridhara, R, Eisenberger, M A, Sinibaldi, V J, Reyno, L M, Egorin, M J

“…We evaluated the surrogate role of serum prostate-specific antigen (PSA) using prospectively collected information from patients with hormone-refractory…”
Get more information

Suramin, an active drug for prostate cancer: interim observations in a phase I trial by Eisenberger, M A, Reyno, L M, Jodrell, D I, Sinibaldi, V J, Tkaczuk, K H, Sridhara, R, Zuhowski, E G, Lowitt, M H, Jacobs, S C, Egorin, M J

“…Previous studies indicate that suramin may be an active agent for treatment of solid tumors. The clinical use of suramin is complicated by a broad spectrum of…”
Get more information

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer by Eisenberger, M A, Sinibaldi, V J, Reyno, L M, Sridhara, R, Jodrell, D I, Zuhowski, E G, Tkaczuk, K H, Lowitt, M H, Hemady, R K, Jacobs, S C

“…This phase I study was designed with the following objectives: (1) to describe the overall and dose-limiting toxicity (DLT) of suramin administered by…”
Get more information

Phase II Trial of N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and Doxorubicin Chemotherapy in Metastatic Breast Cancer: A National Cancer Institute of Canada Clinical Trials Group Study by KHOO, K, BRANDES, L, REYNO, L, ARNOLD, A, DENT, S, VANDENBERG, T, LEBWOHL, D, FISHER, B, EISENHAUER, E

“…This multicenter phase II trial investigated the efficacy and toxicity of a combination of the novel intracellular histamine antagonist,…”
Get full text

Development and validation of a pharmacokinetically based fixed dosing scheme for suramin by Reyno, L M, Egorin, M J, Eisenberger, M A, Sinibaldi, V J, Zuhowski, E G, Sridhara, R

“…We used population pharmacokinetic-parameter estimates and designed a fixed dosing schedule to maintain plasma suramin concentrations between 100 and 300…”
Get more information

A phase I-II study of 9-cis retinoic acid and interferon-α2b in patients with advanced renal-cell carcinoma: An NCIC Clinical Trials Group study by Miller, W. H., Reyno, L. M., Loewen, G. R., Huan, S., Winquist, E., Moore, M., Cato, A., Jaunakais, D., Truglia, J. A., Matthews, S., Dancey, J., Eisenhauer, E.

“…Although advanced renal-cell carcinoma (RCC) responds poorly to standard therapies, phase I–II trials have shown activity for combinations of interferon-α2b…”
Get full text

Suramin by Eisenberger, M A, Reyno, L M

Get more information

Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers by Grunfeld, Eva, Coyle, Doug, Whelan, Timothy, Clinch, Jennifer, Reyno, Leonard, Earle, Craig C, Willan, Andrew, Viola, Raymond, Coristine, Marjorie, Janz, Teresa, Glossop, Robert

“…The vital role played by family caregivers in supporting dying cancer patients is well recognized, but the burden and economic impact on caregivers is poorly…”
Get full text

Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer by Reyno, L M, Egorin, M J, Canetta, R M, Jodrell, D I, Swenerton, K D, Pater, J L, Burroughs, J N, Novak, M J, Sridhara, R

“…To determine (1) the impact of cyclophosphamide 600 mg/m2 on previously defined relationships between carboplatin area under the plasma concentration versus…”
Get more information

Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer by Jodrell, D I, Reyno, L M, Sridhara, R, Eisenberger, M A, Tkaczuk, K H, Zuhowski, E G, Sinibaldi, V J, Novak, M J, Egorin, M J

“…This study aimed to (1) develop a population pharmacokinetic model for suramin; (2) use Bayesian methods to assess suramin pharmacokinetics in individual…”
Get more information

126P Evaluation of myeloid targeting agents, PY159 and PY314, in two dose expansion phase Ib trials in platinum-resistant ovarian cancer by Yeku, O.O., Barve, M., Tan, W.W., Wang, J.S., Patnaik, A., Lorusso, P., Naqash, A-R., Dowlati, A., Fu, S., Gordon, M., Hubbard, J., Kummar, S., Kyriakopoulos, C.E., Schenk, E., Deegan, D., Liang, L., Li, Y., Reyno, L., Chamberlain, M., Winer, I.

Get full text

Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin by Sridhara, R, Eisenberger, M A, Sinibaldi, V J, Reyno, L M, Egorin, M J

“…Hormone-refractory prostate cancer (HRPC) patients often have nonmeasurable disease. In such patients, predictive biomarkers other than tumor response may be…”
Get full text

Potentiation by interleukin 1α of cisplatin and carboplatin antitumor activity: Schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model by MING-JEI CHANG, WEI-DONG YU, REYNO, L. M, MODZELEWSKI, R. A, EGORIN, M. J, ERKMEN, K, VLOCK, D. R, FURMANSKI, P, JOHNSON, C. S

“…We have previously demonstrated that the cytokine interleukin 1 alpha (IL-1 alpha) significantly potentiates the antitumor activity of a variety of…”
Get full text

Modeling toxicity and response in carboplatin-based combination chemotherapy by Egorin, M J, Reyno, L M, Canetta, R M, Jodrell, D I, Swenerton, K D, Pater, J L, Burroughs, J N, Novak, M J, Sridhara, R

“…Data from women with advanced ovarian cancer (International Federation of Gynecology and Obstetrics stage III or IV) were analyzed to evaluate the…”
Get more information

Offering a choice between two adjuvant chemotherapy regimens: a pilot study to develop a decision aid for women with breast cancer by Irwin, Ellen, Arnold, Andrew, Whelan, Timothy J., Reyno, Leonard M., Cranton, Patricia

“…Background: The primary objective of this study was to develop a decision aid which would encourage and assist patients to become involved in treatment…”
Get full text